CD34 and acute myeloid leukemia: Taken together, these results indicated that both PepE and DMAPE exhibited strong and specific toxicity to Ara-C resistant primary CD34+ AML cells, while DMAPE showed less toxic effects than its parent drug PepE at high doses.